期刊文献+

不同剂量阿托伐他汀对糖尿病患者应用对比剂后肾功能的影响 被引量:4

Effect of different doses of atorvastatin on renal function in patients with diabetes mellitus undergoing visualization
下载PDF
导出
摘要 目的 观察阿托伐他汀对糖尿病患者应用对比剂后肾功能的影响.方法 将60例拟行造影术的糖尿病患者完全随机分为20 mg阿托伐他汀组和80 mg阿托伐他汀组,各30例,分别于术前3d每晚服用阿托伐他汀20、80 mg.术前和术后第1、2天检测血清胱抑素C(CysC)、肾小球滤过率(GFR)、尿视黄醇结合蛋白(RBP)、高敏C反应蛋白(hs-CRP)、尿素氮和血清肌酐(Scr)并计算肌酐清除率(Ccr).结果 20 mg阿托伐他汀组术前CysC、GFR、尿RBP、hs-CRP分别为(0.78 ±0.35) mg/L、(104±16) ml/min、(0.47±0.15) mg/L、(3.7±1.0)mg/L,术后第1天分别为(1.00±0.46) mg/L、(85±8)ml/min、(0.80 ±0.19) mg/L、(7.8 ±1.1)mg/L,术后第2天分别为(0.94±0.14) mg/L、(93±18) ml/min、(0.71±0.23) mg/L、(9.9±1.2) mg/L.80 mg阿托伐他汀组术前CysC、GFR、尿RBP、hs-CRP分别为(0.79±0.41)mg/L、(102±7)ml/min、(0.43 ±0.23) mg/L、(3.6 ± 1.7)mg/L,术后第1天分别为(0.88 ±0.41) mg/L、(94±16) ml/min、(0.54±0.20) mg/L、(5.7±1.7) mg/L,术后第2天分别为(0.82±0.12) mg/L、(100±16) ml/min、(0.47±0.19) mg/L、(6.8±1.6) mg/L.与20 mg阿托伐他汀组比较,术后第1、2天,80 mg阿托伐他汀组血清CysC、hs-CRP、尿RBP水平明显降低(P<0.05),GFR明显升高(P<0.05).与术前比较,术后第1天2组CysC、hs-CRP、尿RBP均明显升高,GFR明显下降(P<0.05);与术后第1天比较,术后第2天2组CysC、尿RBP均明显下降,GFR明显升高(P<0.05).2组均未见发生造影剂肾病,造影前后尿素氮、Scr、Ccr差异无统计学意义(P>0.05).结论 糖尿病患者造影前应用大剂量阿托伐他汀能改善造影剂引起肾功能损害. Objective To observe the effect of different doses of atorvastatin on renal impairment caused by contrast agent in patients with diabetes mellitus (DM) who underwent visualization.Methods A total of 60 DM patients undergoing visualization were randomly divided into 20 mg atorvastatin group and 80 mg atorvastatin group ; in each group,patients took 20 mg or 80 mg atorvastatin daily 3 days before visualization.The levels of high-sensitivity CRP (hs-CRP),cystain C (CysC),urinary retinal binding protein (RBP),serum creatinine(Scr) and blood urea nitrogen (BUN) were detected before,1 and 2 days after visualization.The creatinine clearance rate (Ccr) and glomerular filtration rate(GFR) were calculated.Results CysC,GFR,urine RBP,hs-CRP in 20 mg statin group were (0.78 ± 0.35)mg/L,(104 ± 16)ml/min,(0.47 ± 0.15)mg/L and(3.7 ± 1.0)mg/L before operation ;on postoperative 1 d,they were (1.00 ± 0.46) mg/L,(85 ± 8) ml/min,(0.80 ± 0.19) mg/L,(7.8 ± 1.1)mg/L,respectively; on postoperative 2 d,they were(0.94 ±0.14) mg/L,(93 ± 18) ml/min,(0.71 ±0.23) mg/L,(9.9 ± 1.2) mg/L,respectively.CysC,GFR,urine RBP,hs-CRP in 80 mg statin group were (0.79 ± 0.41) mg/L,(102 ± 7) ml/min,(0.43 ± 0.23) mg/L,(3.6 ± 1.7) mg/L,before operation ; on postoperative 1 d,they were(0.88 ±0.41) mg/L,(94 ± 16) ml/min,(0.54 ±0.20) mg/L,(5.7 ± 1.7) mg/L,respectively; on post-operative 2 d,they were (0.82 ± 0.12) mg/L,(100 ± 16) ml/min,(0.47 ± 0.19) mg/L,(6.8 ± 1.6) mg/L,respectively.Compared with those in 20 mg statin group,serum CysC,hs-CRP,urine RBP levels in 80 mg statin group were significantly lower after operation(P 〈 0.05).Compared with the preoperative levels in two groups,CysC,hs-CRP and uric RBP were significantly elevated on postoperative 1 d and GFR was significantly decreased (P 〈 0.05).CIN did not occur in two groups; urea nitrogen,Scr,Ccr had no differences before and after angiography (P 〉 0.05).Conclusion Pretreatment with high dose of atorvastatin 3 days for DM patients before visualization can effectively alleviate the renal impairment caused by contrast agent.
出处 《中国医药》 2014年第12期1756-1760,共5页 China Medicine
关键词 糖尿病 阿托伐他汀 高敏C反应蛋白 Diabetes mellitus Atorvastatin High-sensitivity C-reactive protein
  • 相关文献

参考文献28

  • 1Slocum NK,Grossman PM,Moscucci M,et al.The changing definition of contrast-induced nephropathy and its clinical implications:insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)[J].Am Heart J,2012,163(5):829-834.
  • 2曹厚德.第二十届长城国际心脏病学会议关于对比剂肾病形成的专家共识[J].临床放射学杂志,2010,29(1):57-57. 被引量:15
  • 3Patti G,Nusca A,Chello M,et al.Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve longterm outcome in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2008,101 (3):279-285.
  • 4周益,袁伟杰.短期大剂量他汀类药物对冠状动脉造影患者对比剂肾病预防作用的荟萃分析[J].中华内科杂志,2011,50(11):942-946. 被引量:17
  • 5Solomon R,Dauerman HL.Contrast-induced acute kidney injury.Circulation,2010,122 (23):2451-2455.
  • 6Seeliger E,Sendeski M,Rihal CS,et al.Contrast-induced kidney injury:mechanisms,risk factors,and prevention[J].Eur Heart J,2012,33(16):2007-2015.
  • 7Patti G,Ricottini E,Nusca A,et al.Short-term,high-dose Atoryastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN[atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy]trial[J].Am J Cardiol,2011,108(1):1-7.
  • 8薛艳,苏津自(审校).对比剂肾病及他汀类药物对其预防的研究进展[J].中国心血管病研究,2011,9(6):457-460. 被引量:4
  • 9Yen HW,Lee HC,Lai WT,et al.Effects of acetylcysteine and probucol on contrast medium-induced depression of intrinsic renal glutathione peroxidase activity in diabetic rats[J].Arch Med Res,2007,38 (3):291-296.
  • 10Yang D,Lin S,Yang D,et al.Effects of short-and long-term hypercholesterolemia on contrast-induced acute kidney injury[J].Am J Nephrol,2012,35(1):80-89.

二级参考文献156

共引文献146

同被引文献57

  • 1郑麒,刘庆新.短暂性脑缺血发作颅内动脉粥样硬化的血清CysC水平及其药物治疗评价[J].中国生化药物杂志,2014,34(5):54-57. 被引量:16
  • 2薛文鑫,李静,李怡文,张藜莉.强化瑞舒伐他汀对经皮冠脉介入术后对比剂肾病预防效果的Meta分析[J].中国生化药物杂志,2014,34(6):83-86. 被引量:8
  • 3陈灏珠.实用内科学[M]12版.北京:人民卫生出版社,2005.1746-1750.
  • 4陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
  • 5Darwish T. An evidence-based approach to minimise con- trast induced nephropathy [J]. N Z Med J,2009,122(1299) : 39-41.
  • 6Madrazo GZ, Arias GM. Contrast nephropathy. Review and prophylaxis !1I [J]. Rev Clin Esp,2008,208 (10):517- 519.
  • 7Zager RA, Johnson AC, Hanson SY. Radiographic contrast media-induced tubular injury:evaluation of oxidant stress and plasma membrane integrity [J]. Kidney Int,2003,64 ( 1 ) : 128-139.
  • 8陈纪言.对比剂肾病发病机制的深入探索[J].中国医学论坛报,2009,35(30):59-62.
  • 9Hefts BR, Schneider E, 0buchowski N, et al. Probability of reduced renal function after contrast-enhanced CT:a model based on serum creatinine level,patient age,and estimated glomerular filtration rate [J]. AJR Am Roentgenol, 2009,193(2) :494-500.
  • 10Jo SH, Koo BK, Park JS, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high- dose simvastatin in patients with renal insufficiency un- dergoing coronary angiography (PROMISS)trial-a ran- domized controlled study [J]. Am Heart J,2008,155(3): 499, e 1-eS.

二级引证文献66

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部